Oryzon Genomics (MEX:ORYN) Total Operating Expense: MXN495.38 Mil (TTM As of Mar. 2026)


MEX:ORYN Oryzon Genomics SA MEX:ORYN
31 GF Score
Price MXN48.59
View Full Analysis

What is Oryzon Genomics Total Operating Expense?

Oryzon Genomics MEX:ORYN 31 Total Operating Expense is MXN495.38 Mil as of Mar. 2026. GuruFocus rates MEX:ORYN with a GF Score™ of 31/100.

Oryzon Genomics's Total Operating Expense for the three months ended in Mar. 2026 was MXN120.21 Mil. Oryzon Genomics's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was MXN495.38 Mil.

Oryzon Genomics Total Operating Expense Related Terms

Oryzon Genomics Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Oryzon Genomics's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oryzon Genomics Total Operating Expense Chart

Oryzon Genomics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 391.96 433.28 347.07 249.12 346.02

Oryzon Genomics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 76.82 83.94 93.35 197.88 120.21
MEX:ORYN
31GF Score
Oryzon Genomics SA MEX:ORYN
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oryzon Genomics Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN495.38 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of MXN495.38 Mil mean?
Oryzon Genomics (MEX:ORYN) has a Total Operating Expense of MXN495.38 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Oryzon Genomics and its competitors.
Is Oryzon Genomics' Total Operating Expense too high?
Oryzon Genomics' current Total Operating Expense is MXN495.38 Mil. Overall, Oryzon Genomics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Oryzon Genomics' Total Operating Expense compare to VRTX and REGN?
Oryzon Genomics' Total Operating Expense of MXN495.38 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Oryzon Genomics and its competitors. Oryzon Genomics's current Total Operating Expense is MXN495.38 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oryzon Genomics stock overvalued right now?
Oryzon Genomics (MEX:ORYN) has a current Total Operating Expense of MXN495.38 Mil. The current Total Operating Expense is MXN495.38 Mil. Oryzon Genomics' overall GF Score™ is 31/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Oryzon Genomics (MEX:ORYN), the current Total Operating Expense is MXN495.38 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oryzon Genomics Business Description

Address Sant Ferran 74, Cornellà de Llobregat, Barcelona, ESP, 08940
Oryzon Genomics SA is a clinical stage biopharmaceutical company and engaged in the development of epigenetics-based therapeutics. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases.
31GF Score

Get the complete analysis for MEX:ORYN

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN48.59
Price